Gossamer Bio (GOSS) Depreciation & Amortization (CF) (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Depreciation & Amortization (CF) of $5000.0 for Q1 2026, down 16.67% year-over-year from $6000.0 in Q1 2025, and down 16.67% quarter-over-quarter from $6000.0 in Q4 2025.
Gossamer Bio (GOSS) Depreciation & Amortization (CF) (2018 - 2026) Analysis & Trends
Gossamer Bio's Depreciation & Amortization (CF) history runs 9 years deep, the most recent figure standing at $5000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 16.67% year-over-year to $5000.0; the TTM figure through Mar 2026 stood at $23000.0 (down 96.25% YoY), while the FY2025 annual figure was $24000.0, down 97.12% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $5000.0, down from $6000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $500000.0 in Q2 2022, with the low at $5000.0 in Q1 2026.
- The 5-year median for Depreciation & Amortization (CF) is $300000.0 (2024), against an average of $263941.2.
- The sharpest annual moves came in 2022 and 2025: Depreciation & Amortization (CF) increased 25.0% in 2022, then slumped 98.0% in 2025.
- Gossamer Bio's Depreciation & Amortization (CF) stood at $432000.0 in 2022, then retreated by 28.94% to $307000.0 in 2023, then slumped by 64.82% to $108000.0 in 2024, then sank by 94.44% to $6000.0 in 2025, then fell by 16.67% to $5000.0 in 2026.
- Business Quant data shows GOSS's Depreciation & Amortization (CF) at $5000.0 in Q1 2026, $6000.0 in Q4 2025, and $6000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Sep 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 108,000.00 |
| Dec 31, 2024 | 108,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 300,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Mar 31, 2024 | 259,000.00 |
| Dec 31, 2023 | 307,000.00 |
| Dec 31, 2023 | 307,000.00 |